- Home
- WAFU vs BTAI Comparison
WAFU vs BTAI Comparison
Compare WAFU & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAFU
- BTAI
- Stock Information
- Founded
- WAFU 1999
- BTAI 2017
- Country
- WAFU China
- BTAI United States
- Employees
- WAFU N/A
- BTAI N/A
- Industry
- WAFU Other Consumer Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- WAFU Real Estate
- BTAI Health Care
- Exchange
- WAFU Nasdaq
- BTAI Nasdaq
- Market Cap
- WAFU 7.1M
- BTAI 6.6M
- IPO Year
- WAFU 2019
- BTAI 2018
- Fundamental
- Price
- WAFU $1.83
- BTAI $2.13
- Analyst Decision
- WAFU
- BTAI Buy
- Analyst Count
- WAFU 0
- BTAI 4
- Target Price
- WAFU N/A
- BTAI $37.00
- AVG Volume (30 Days)
- WAFU 46.3K
- BTAI 279.4K
- Earning Date
- WAFU 01-01-0001
- BTAI 03-11-2025
- Dividend Yield
- WAFU N/A
- BTAI N/A
- EPS Growth
- WAFU N/A
- BTAI N/A
- EPS
- WAFU N/A
- BTAI N/A
- Revenue
- WAFU $7,223,220.00
- BTAI $2,276,000.00
- Revenue This Year
- WAFU N/A
- BTAI $105.36
- Revenue Next Year
- WAFU N/A
- BTAI $46.93
- P/E Ratio
- WAFU N/A
- BTAI N/A
- Revenue Growth
- WAFU N/A
- BTAI 83.25
- 52 Week Low
- WAFU $1.46
- BTAI $2.10
- 52 Week High
- WAFU $2.63
- BTAI $56.00
- Technical
- Relative Strength Index (RSI)
- WAFU 56.26
- BTAI 28.68
- Support Level
- WAFU $1.63
- BTAI $2.18
- Resistance Level
- WAFU $1.81
- BTAI $2.60
- Average True Range (ATR)
- WAFU 0.12
- BTAI 0.44
- MACD
- WAFU 0.00
- BTAI -0.08
- Stochastic Oscillator
- WAFU 55.58
- BTAI 0.94
About WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services, and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.